TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

IMIQUIMOD

IMIQUIMOD Interferon Inducers
Oncology Approved 2010-02-25
9
Indications
--
Phase 3 Trials
16
Years on Market

Details

Status
Prescription
First Approved
2010-02-25
Routes
TOPICAL
Dosage Forms
CREAM

IMIQUIMOD Approval History

Loading approval history...

What IMIQUIMOD Treats

4 indications

IMIQUIMOD is approved for 4 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Actinic Keratosis
  • Basal Cell Carcinoma
  • External Genital Warts
  • Perianal Warts
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IMIQUIMOD FDA Label Details

Pro

Indications & Usage

Imiquimod Cream is indicated for the topical treatment of: • Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults. • Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults with a maximum tumor diameter of 2.0 cm on trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured. • External genital and perianal warts (EGW) in immunocompetent patients 12 years of a...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.